Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.

摘要: Background Sirolimus is a potent immunosuppressive drug that has been shown to decrease the incidence of rejection post renal transplantation. Dyslipidemia well recognized side effect sirolimus therapy, which may have an impact on patient survival and post-transplant cardiac morbidity mortality. It unknown whether sirolimus-induced dyslipidemia aggravated by concomitant use tacrolimus also affect lipid profile. To compare induced in based vs. free regimens transplant recipients. Material/methods Patients who received kidney transplantation for at least nine sequential months were included our retrospective study. Forty-eight recipients divided into 2 groups regimen; Group 1 prednisone, mycophenolate mofetil, while sirolimus, mycophanolate mofetil tacrolimus. Lipid profile was assessed pre-transplantation one, three, six therapy. Results Both showed significant but comparable elevation total cholesterol, LDL-C triglycerides with The evident starting from first month administration remained ninth end follow up period. At month, mean 2.68 2.6 mmol/L (P>0.1) cholesterol 6.3 5.7 group (P>0.1); respectively. By level 3.9 6.2 6.1 Lipid-lowering agents steroids dose similar both groups. Conclusions Hypercholesterolemia hypertriglyceridemia secondary therapy independent use. Lipid-profile should be monitored all receiving as early regardless regimen used.